Objective, Experienced, Knowledgeable Collective of Medical and Scientific
Product Development Leaders
We support healthcare innovation across disease areas and technologies with
specific expertise in key industry segments:
Dr. Goldberg works to drive innovation and value in population health and precision medicine. He serves as a fractional chief medical officer…
Dr. Mina is a physician-scientist and executive leader with a focus at the intersection of biotechnology and data science, AI, healthcare…
Mr. Haack is CEO and co-founder of Cadex Genomics, which focuses on blood-based molecular testing to improve the management of patients with ….
Dr Freeman has been a healthcare executive and educator for 25 years, with a focus on healthcare delivery and population health.
Tiffany Olson currently serves as a Board Member for Castle Biosciences, Telix Pharmaceuticals, Education & Research Foundation for Nuclear Medicine….
Frank Grazzini has worked with numerous technology startups over the past 10+ years where he served primarily as CFO.
Paul Owen most recently served as President and Interim CEO of imaware™ which provides a digital health platform experience that offers advanced home-based testing and monitoring. Paul has had a very productive and successful career in developing and bringing healthcare innovation to market. He previously served as Chief Business Officer and COO for Kailos Genetics and CEO of OneOme, an innovator in precision medicine and pharmacogenetics, co-founded by Mayo Clinic. While leading OneOme they were recognized by Fast Company as the top 22 of 50 most innovative companies in the world, #2 in biotech, awarded 2019 MedTech Breakthrough Award, Best Overall Genomics Company, 2018 Inc. Magazine. Prior to joining OneOme Paul led global commercialization for Invitae, a leader in hereditary disease diagnostics testing. Previously, Paul served as Vice Chair of Global Business Development for Mayo Clinic and was the leader of Mayo Medical Laboratories’ global commercial team – one of the world’s largest full-service reference labs and held leadership roles at Zimmer-Biomet and Boston Scientific.
Paul also serves on the Board of Directors for OpalGenix, Oncodea, and the The Redemption Project and as an Executive Advisor to the University of MN Ventures Group, Decode Health, Phenomix Sciences and Spesana. He received his B.S. in business administration from the University of Wisconsin – Stout and lives in Minneapolis, MN.
Dr. Tabibiazar is a seasoned executive with leadership experience in the healthcare and biopharma industries, including venture capital, pharmaceuticals and diagnostics. As a clinician-entrepreneur and as managing director of 526 Ventures, he has focused on creating new ventures in the form of new companies or spinouts to translate innovative science into commercially viable products – with an outstanding track record particularly in advanced biopharmaceutical development strategies. Dr. Tabibiazar serves as Chair at SalioGen Therapeutics and previously led Aravive Biologics as CEO, served as SVP, Corporate Development and Business Strategy at Twist Bioscience and as a Venture Partner at Bay City Capital as well as several other roles. Prior to moving to industry, Dr. Tabibiazar was a practicing cardiologist and a faculty member at Stanford University, having trained as a physician scientist at Harvard Medical School and a cardiologist at Stanford Medical Center.
Dr. Cockerill has been a leader in development and commercialization of diagnostics and medical services across disease areas and technologies. He most recently served as the CEO and CMO of Analyte Health, a leader in virtual care diagnostic services. Before joining Analyte Health, Dr. Cockerill was the Chair of the Department of Laboratory Medicine and Pathology, Mayo Clinic, and President and CEO of Mayo Medical Laboratories. While at Mayo he also carried a named professorship, the Ann and Leo Markin Professor of Medicine and Microbiology at the Mayo Medical School. Dr. Cockerill and his research team at Mayo developed numerous real-time PCR assays, which have significant advantages over conventional culture-based assays, and include the first commercially available rapid PCR test for Anthrax. This work has resulted in 10 patents and 56 licensed technologies. Recently, Dr. Cockerill provided a pivotal role for one of the first clinical studies of self-swabbing for COVID-19 infection in the US. He helped coordinate the swift development and execution of the study, along with the Gates Foundation, Everett Clinic (United Healthcare) and Quest Diagnostics, in March 2020 which resulted in one of the earliest FDA emergency use self-testing methods for COVID-19.
Dr. Cockerill is Board Certified in Internal Medicine, Infectious Diseases and Clinical Microbiology. He has served as Chair of the Subcommittee on Antimicrobial Susceptibility Testing, Clinical Laboratory Standards Institute (CLSI), Chair, Microbiology Devices Panel of the Medical Devices Advisory Committee of the US FDA, Board Member and Program Director, of the Association for Molecular Pathology (AMP), Director, American Clinical Laboratory Association Board; Director, Board of Scientific Counselors of the Centers for Disease Control and Prevention (CDC) and Editor, Journal of Clinical Microbiology. Dr. Cockerill was the recipient of the BD Award, sponsored by the American Society for Microbiology (ASM), the highest honor bestowed upon a clinical microbiologist in the United States.
Dr. Bender spent 25 years in clinical practice the majority spent serving as the Medical Director for Oncology / Hematology for Kaiser Permanente in San Diego. In 2002 he transitioned to the diagnostic industry where he has been the Medical Director for Hematology / Oncology for Quest Diagnostics, Inc. and the CMO for Agendia, Inc. and Signal Genetics, Inc., both molecular diagnostics companies. He has also served on the executive board of the San Diego Hospice and American Cancer Society. He continues to teach at the UCLA School of Medicine and serves as an expert reviewer in oncology for the Medical Board of California and was recently selected to be a consultant for the Medical Devices Advisory Committee of the FDA. Dr. Bender is the author or co-author of over 80 peer-reviewed scientific articles and numerous book chapters and has been invited to speak all over the world as an expert in oncology diagnostics. He continues in clinical practice as a member of the Oncology Institute.
Dr. Kuhn is a Professor at USC, the director of USC’s CSI-Cancer Institute. His vision of translating innovation in research to meaningful products for patient care is driving his everyday efforts. He also serves as Dean’s Professor of Biological Sciences, Professor of Medicine, Aerospace & Mechanical Engineering, and Biomedical Engineering at USC as well as Director of the USC Michelson Convergent Science Institute in Cancer (CSI-Cancer) and the deputy director of the Convergent Science – Virtual Cancer Center. He holds a chair as Honorary Professor of Cancer Science at the University of Manchester in the United Kingdom.Dr. Kuhn is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany. Previously, Dr. Kuhn held a faculty appointment at Stanford where he established the structural genomics research enterprise and focused his research on technology developments in structural biology that were utilized by breakthrough research such as Dr. Roger Kornberg’s (Nobel prize 2006) structure determination of the RNA Polymerase. Dr. Kuhn joined Scripps and established the Physics Oncology program where he advanced technologies that led to the structure determination of the human b2AR GPCR with collaborators including Dr. Brian Kobilka (Nobel prize 2012).
His research and inventions have resulted in over 300 peer-reviewed publications, which have been cited over twenty-thousand times. Technologies developed by Dr. Kuhn have been the foundation of multiple healthcare companies and his research has been licensed to numerous companies.
Dr. Goldberg works to drive innovation and value in population health and precision medicine. He serves as a fractional chief medical officer, providing clinical strategy and operations leadership for early-stage companies serving self-insured employers, health plans and physician organizations. He has published on employee health and comprehensive medication management enhanced with pharmacogenomics. Steve most recently served as VP, Chief Health Officer, Employee and Population Health for Quest Diagnostics. In that role he led employee health, where his team drove improved member experience, improved population health and bent cost trends for the company’s 60,000 plan members.
Before joining Quest, Steve was SVP and CMO at WellCare Health Plans, a multi-billion-dollar provider of government-sponsored managed care services. He has previously served in executive medical management roles with Aetna, Express Scripts, Humana and Excellus BCBS. Steve earned an MD from Jefferson Medical College, completed the United Health Services Family Medicine Residency in Binghamton, New York, and earned an MBA at Binghamton University. He is board certified in Family Medicine and maintains a part-time clinical practice in Louisville, KY.
Dr. Pearle is the Chief of the Sports Medicine Institute at the Hospital for Special Surgery in New York and Professor of Orthopedic Surgery at Weill Cornell Medical College. He is a Team Physician for the New York Mets and an Orthopedic Consultant for the UFC. Dr. Pearle is an internationally known innovator in orthopedics including his pioneering clinical work in robotic knee surgery, partial knee replacement, and ACL surgery. Dr Pearle created the first computer assisted surgery laboratory in the US, which now collaborates closely with the Biomechanic laboratory at Hospital for Special Surgery. A former Editor-in-Chief of the Orthopedic Journal Techniques in Knee Surgery, Dr. Pearle has published over 200 peer review articles focusing primarily on outcomes of robotic knee surgery, foundational biomechanical studies on ACL function, and novel uses of MRI in prevention and management of ACL injury. In 2007, Dr. Pearle performed the first robotic partial knee replacement in the New York region. He has now performed thousands of these procedures and is the leading world expert and thought leader on the use of robotic technology for partial and total knee replacement.
Dr. Robson has a long career in healthcare innovation with significant experience in medical informatics, digital health and retail pharmacy. He currently serves as CMO of Imaware, an at-home testing company and MDisrupt, a digital healthcare company providing access to a network of medical experts to assist in development and implementation of healthcare solution development and deployment. He previously served senior roles at Walgreens including Chief Medical Officer where we he oversaw medical aspects of the pharmacy business and COVID response as well as numerous programs in digital health, consumer engagement and collaborative programs in genetics, evidence-based medicine and many other areas. Prior to Walgreens Dr. Robson served as Chief Medical Information Officer for Adventist Health Partners a leading health system in the Midwest. At Walgreens he was the recipient of the Global Divisional Leadership and Champion of Champions award for Pharmacy Safety and at Adventist he was given the Distinguished Leadership Award. Dr. Robson trained in medicine at Midwestern University and then received his MBA in Healthcare Delivery Science from Dartmouth.
Dr. Mina is a physician-scientist and executive leader with a focus at the intersection of biotechnology and data science, AI, healthcare product development, and regulation. Dr. Mina was most recently CSO and President Research and Public Health for eMed, a company focused on consumer centric testing solutions delivered with virtual medical supervision. He has served as a fractional CMO and BOD member for Quantum SI, a protein sequencing company, and a fractional CMO for Detect (at-home infectious diseases testing) and LivePerson (healthcare AI). Dr. Mina received his MD and PhD from Emory with a focus on Population Biology, Infectious Diseases and Evolution. He completed post-doctoral fellowships at Princeton in Applied Math in Infectious Diseases and at Harvard Medical School in Genetics and Immune Engineering. He also completed a residency in Clinical Pathology at Harvard Mass General Brigham and held a faculty appointment as Assistant Professor of Epidemiology, Immunology and Pathology at Harvard Medical School and the Broad Institute. While in this capacity, Dr. Mina was the medical director for the Broad’s COVID-19 testing services and had a major impact in the field through those services as well as through his work in educating the emerging field on the appropriate role of antigen vs. PCR testing. Dr. Mina has been widely recognized with numerous awards for his innovative efforts in healthcare during his career.
Mr. Haack is CEO and co-founder of Cadex Genomics, which focuses on blood-based molecular testing to improve the management of patients with metastatic cancer. He has over 20 years of experience in life sciences. He started his career at Genentech where he led the commercial operations team and the successful launch of Rituxan and Herceptin. He was an early employee at Genomic Health, where he helped lead and was instrumental in the launch and commercial success of all three Oncotype DX products. Under Mr. Haack’s leadership, Genomic Health grew from a company with no revenue to over $300M in annual revenues. Mr. Haack also led the launch of Genomic Health in Europe, where he led the start-up of their headquarters in Geneva and the establishment of commercial teams in the United Kingdom, Italy and Germany. Mr. Haack holds an MA degree in Economics and Econometrics from Cal State University Hayward and lives in Redwood City, CA.
Dr. Freeman has been a healthcare executive and educator for 25 years, with a focus on healthcare delivery and population health. She is currently the President of Creative HealthCare Initiatives, LLC, focused on addressing challenges in healthcare through population health strategies, transformative change, education, and innovation. A faculty member of the American College of Physician Leadership, she develops and teaches courses in strategic planning for physician executive graduate degree programs.
Prior to her recent move to Arizona, Dr. Freeman was Provost and Senior Vice President, and the Robert C. and Naomi T. Borwell Presidential Professor, at Rush University in Chicago where she served as the chief operating officer of the university. Dr. Freeman was a co-founder and co-director of the Rush Institute for Health Equity. She also initiated the office of human centered design. Dr. Freeman served previously as the CMO, Vice Dean of Health Care Systems and the founding President of the Temple Center for Population Health at Temple University and Temple University Health System in Philadelphia. Under Dr. Freeman’s leadership, Temple was the recipient of several grants to improve health care in North Philadelphia. Dr. Freeman is a reviewer for Population Health Management and the Journal of HealthCare Quality.
A graduate of the Michigan State University College of Human Medicine, Dr. Freeman completed both her residency in internal medicine and fellowship in endocrinology and metabolism at the Mayo Clinic Graduate School of Medicine, Rochester, Minnesota. She holds a Master of Science degree in Preventive and Administration Medicine from the University of Wisconsin, Madison. Dr. Freeman is a Fellow of the American Association of Physician Leadership and the American Association of Clinical Endocrinologists.
Tiffany Olson currently serves as a Board Member for Castle Biosciences, Telix Pharmaceuticals, Education & Research Foundation for Nuclear Medicine, and Molecular Imaging, and on the Langham Logistics Advisory board. Other boards have included Asuragen, BioTelemetry Inc, ThermoGenesis, Little Rapids Corporation and Chairwoman of Diaceutics. She is a thought leader in the healthcare industry, with significant experience leading healthcare innovation in several industry segments.
Tiffany was formerly the president of Nuclear & Precision Health Solutions at Cardinal Health which develops, manufactures, compounds, dispenses and delivers radiopharmaceuticals. Prior to Cardinal Health, Tiffany was President of NaviMed, a company focused on personalizing medicine through innovative diagnostics. She also worked for Eli Lilly and Company, where she was tasked with leading the effort to formulate the strategy to create and commercialize diagnostics and companion diagnostics. Tiffany worked for Roche Diagnostics for many years, where she attained the position of President and CEO of Roche Diagnostics Corporation. Prior to this appointment, Tiffany was the Global Head of Market Development and Quality located in Basel, Switzerland. Other positions she held with the company included Vice President of Roche Molecular Diagnostics and Vice President of Corporate Accounts.
Tiffany was recognized as one of the “10 Best Women Leaders of 2020” by Industry Era. She was the first woman to receive the Life Science Alley Luminary Award. Tiffany received the Woman of Wellness Award and the American Cancer Society Leadership Award for her volunteer work in oncology. Tiffany has a bachelor’s degree in business from the University of Minnesota and a master’s degree from St. Thomas University in Minnesota.
Frank Grazzini has worked with numerous technology startups over the past 10+ years where he’s served primarily as CFO. In addition, he has co-founded two ventures and has been an advisor to several others. In these roles, Frank developed expertise in company formation, team and strategic plan development, and execution in an early-stage environment. Prior to his work with early-stage companies, Frank spent 10 years in corporate finance within publicly held global manufacturers. Frank has an MBA from the Carlson School at the University of Minnesota.
Mark Y. Liu is a corporate and capital markets attorney with nearly 20 years of experience advising companies in various stages of development with respect to investments and financing, corporate governance and M&A. Mr. Liu has counseled companies and investment banks in initial public offerings (IPOs) on the New York Stock Exchange, the Nasdaq Global Select Market, and the Stock Exchange of Hong Kong, and has negotiated cross-border capital markets transactions across industries, including biotechnology. A former pre-med, Mr. Liu holds a Bachelor of Science in Business Administration from Washington University in St. Louis and a J.D. from the University of Iowa College of Law.
Paul Boranian is an accomplished operations manager with experience in the healthcare consulting industry. Currently, Paul serves as the head of operations for Trusted Health Advisors. In this role, Paul is responsible for managing all facets of the brand, including client relations, project management, and financial operations. Paul brings exceptional skills in operations management, digital marketing, financial management and communications and has been instrumental in the founding and success of Trusted Health Advisors.
Prior to joining Trusted Health Advisors, Paul co-founded Golf Daddy, a wildly popular golf training aid company that has taken social media by storm. His expertise in media management, computer science, videography and editing has been critical to the success of Golf Daddy. This experience has also given Paul a unique perspective on the importance of strong operations management and client relations, which he has brought to his work with Trusted Health Advisors. Paul graduated from Pepperdine with a degree BS in Business Administration.
